Shots:
- The P-III PROTECTIVE-1 study assessing plinabulin as monothx vs Pegfilgrastimfor in patients with CIN. The US FDA accepted the NDA & PR and the anticipated PDUFA date is Nov 30, 2021
- The trial met its 1EP i.e plinabulin (day 1 dose as CT) demonstrates non-inferiority against Pegfilgrastim, improvement in bone pain, and platelet count. The therapy further supports the reduction of FN, hospitalization @ 1 week, following CT
- Additionally, four studies program includes P-II/III PROTECTIVE-1 & P-II/III PROTECTIVE-2 studies supports the combination regimen of plinabulin and G-CSF to prevent CIN in all solid tumors and CT
Click here to read full press release/ article | Ref: GlobeNewswire | Image: BeyondSpring
The post BeyondSpring Presents Results of Plinabulin in P-III PROTECTIVE-1 Study for Prevention of Chemotherapy-Induced Neutropenia at ASCO 2021 first appeared on PharmaShots.
